Plain-English translation of NCT06103682 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study is testing whether adding a special type of radiation treatment called stereotactic ablative radiotherapy (SABR) — or a minimally invasive procedure performed by an interventional radiologist — can help people with non-small cell or small-cell lung cancer who are currently on systemic therapy (treatment that travels through the whole body) but have developed a few new or growing tumors. The idea is that by treating these limited areas of progression directly, you might be able to stay on your current treatment without needing to switch to a different one.
Sometimes patients on cancer treatment develop just a few new tumor spots while the rest of their disease stays stable. Doctors aren't sure whether adding a focused local treatment to these specific areas can help patients continue their current therapy longer, rather than switching to a new treatment. This trial is designed to answer that question.
You likely qualify if…
You likely don't qualify if…
You will continue taking your current cancer medication as planned. You will then receive either stereotactic ablative radiotherapy (a type of focused radiation delivered in a few sessions) or an interventional radiology procedure (a minimally invasive treatment) to target your new or growing tumor spots. After your radiation or procedure, you'll have regular follow-up visits to check how you're doing, with monitoring continuing for up to 5 years. The main goal is to see whether you can stay on your current treatment without needing to switch medications within the first 3 months after the procedure.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States